ArticleOsteoarthritis and cartilage open2026
A randomized, double-blind, placebo-controlled and dose-ranging study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pregabalin naproxencarbil in acute post-bunionectomy pain: a randomized clinical trial.Pain reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Symptomatic treatment for osteoarthritis (OA) remains a major unmet need. This trial evaluated XG005, a novel, non-opioid, dual-mechanism agent targeting both inflammatory and neuropathic pathways in patients with knee OA. Design: This randomized, double-blind, placebo-controlled study enrolled 318 patients with moderate-to-severe knee OA pain to receive XG005 750 mg, 500 mg, or placebo twice daily for 4 weeks. Efficacy measures included weekly average of daily walking pain (WADWP), Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), Patient Global Impression of Change (PGIC), Sleep Interference Score (SIS), and Short-Form-12 Health Survey (SF-12). Results: The primary efficacy endpoint of improvement from baseline in WADWP at week 4 was statistically greater for the 750 mg group than placebo with least squares mean difference (LSMD) (95 % CI) of -0.55 (-0.94, -0.16). Key secondary endpoints were significantly improved for high- and low-dose XG005 compared to placebo at week 4, with LSMD (95 % CI) of -0.43 (-0.74, -0.13) and -0.4 (-0.78, -0.02) in WOMAC pain, and 5.56 (2.69, 8.42) and 3.74 (0.17, 7.31) in KOOS pain. WOMAC and KOOS stiffness and function, PGIC, SIS and SF-12 mental and general health showed statistically significant improvements over placebo. Patients with neuropathic pain had approximately 2-3-fold greater symptom improvements than patients with nociceptive pain. Mild dizziness and somnolence were most seen in XG005 groups. Conclusion: XG005 demonstrated consistent efficacy in improving OA symptoms with acceptable tolerability. Additional studies in OA patients with neuropathic pain are needed to confirm its dual mechanism advantages. Clinical trial registration: CTR20222406.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.